Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Personalis Inc (PSNL)

Personalis Inc (PSNL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 245,149
  • Shares Outstanding, K 70,648
  • Annual Sales, $ 73,480 K
  • Annual Income, $ -108,300 K
  • EBIT $ -74 M
  • EBITDA $ -65 M
  • 60-Month Beta 1.94
  • Price/Sales 3.25
  • Price/Cash Flow N/A
  • Price/Book 1.43

Options Overview Details

View History
  • Implied Volatility 213.71% ( +50.09%)
  • Historical Volatility 112.70%
  • IV Percentile 64%
  • IV Rank 23.90%
  • IV High 739.47% on 05/23/24
  • IV Low 48.57% on 07/12/24
  • Put/Call Vol Ratio 0.04
  • Today's Volume 26
  • Volume Avg (30-Day) 119
  • Put/Call OI Ratio 0.66
  • Today's Open Interest 1,726
  • Open Int (30-Day) 2,122

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.25
  • Number of Estimates 2
  • High Estimate -0.22
  • Low Estimate -0.28
  • Prior Year -0.46
  • Growth Rate Est. (year over year) +45.65%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.28 +5.79%
on 11/21/24
5.82 -40.38%
on 11/06/24
-1.23 (-26.17%)
since 10/22/24
3-Month
3.28 +5.79%
on 11/21/24
6.26 -44.57%
on 08/23/24
-2.24 (-39.23%)
since 08/22/24
52-Week
1.12 +209.82%
on 02/08/24
7.20 -51.81%
on 08/16/24
+2.10 (+153.28%)
since 11/22/23

Most Recent Stories

More News
Personalis: Q3 Earnings Snapshot

Personalis: Q3 Earnings Snapshot

PSNL : 3.47 (+2.66%)
Why Tempus AI Stock Skyrocketed Nearly 22% Today

It deepened its involvement in a client and peer.

TEM : 58.60 (+11.66%)
PSNL : 3.47 (+2.66%)
Personalis: Q2 Earnings Snapshot

Personalis: Q2 Earnings Snapshot

PSNL : 3.47 (+2.66%)
Personalis: Q1 Earnings Snapshot

Personalis: Q1 Earnings Snapshot

PSNL : 3.47 (+2.66%)
Personalis: Q4 Earnings Snapshot

Personalis: Q4 Earnings Snapshot

PSNL : 3.47 (+2.66%)
Personalis: Q3 Earnings Snapshot

Personalis: Q3 Earnings Snapshot

PSNL : 3.47 (+2.66%)
Personalis: Q2 Earnings Snapshot

Personalis: Q2 Earnings Snapshot

PSNL : 3.47 (+2.66%)
Personalis: Q1 Earnings Snapshot

Personalis: Q1 Earnings Snapshot

PSNL : 3.47 (+2.66%)
Personalis Reports First Quarter 2023 Financial Results

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported financial results for the first quarter ended March 31, 2023 and provided recent business highlights....

PSNL : 3.47 (+2.66%)
Personalis, ABRCC, and Criterium Announce Major Prospective Clinical Trial for Residual and Recurrent Disease Detection in Triple Negative Breast Cancer

Personalis, Inc. (Nasdaq: PSNL) today announced it has partnered with the Academic Breast Cancer Consortium (ABRCC) and Criterium to carry out a prospective clinical trial, B-STRONGER-1 (Breast Cancer-Minimal...

PSNL : 3.47 (+2.66%)

Business Summary

Personalis Inc. is a cancer genomics company. It is engaged in the development of therapies by providing molecular data about each patient's cancer and immune response. Personalis Inc. is based in Menlo Park, California.

See More

Key Turning Points

3rd Resistance Point 3.78
2nd Resistance Point 3.66
1st Resistance Point 3.57
Last Price 3.47
1st Support Level 3.35
2nd Support Level 3.23
3rd Support Level 3.14

See More

52-Week High 7.20
Fibonacci 61.8% 4.88
Fibonacci 50% 4.16
Last Price 3.47
Fibonacci 38.2% 3.44
52-Week Low 1.12

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar